You could be right. I have heard that Teva has strong interest in ADP334 and a strong rumor is that Teva was at Arena's headquarters a few Friday's ago. They could have been there to discuss Belviq and discuss plans for the Israel launch when B is approved or maybe they were talking ADP334?
New partner getting closer as Arena flushes Eisai down the Bemis like the POC they are. Eisai is planning another layoff and potential shutting down of USA operations. Arena has to restructure agreement with new partner in order for new partner to close deal with Eisai in buying the rights to Belviq franchise. Always the possibility of the deal turning into a full-on buyout.
The post is full of holes like Swiss cheese.
Eisai is looking at another layoff and possibly closure of their USA presence. Losing money faster than you can count to three.
Eisai stops sample program. Another cost cutting move. Next will be firing Quintiles reps that also sell Stendra and according to sources, spend more time selling that. Called the path of least resistance.
Arena sold 355 patents to Buddy boy for the grand sum of $355 beating out the other patent pumper by $10.00.
How about 13?weeks of flatness. In ten weeks when Orex has flown past B with the totally useless Eisai at the helm that you still support, one has to question your smarts. You really can't work in Silicon Valley, the majority of people I know there are just not that dumb., Come to your senses, Arena under Jack sucks sheet, Eisai can't give away B. Jack should be arrested as a CEO impostor and will be shortly asked to explain what thevVP of Alliance Management really does. Why smart guy aren't you asking this question?
Explain to me why the price is at 4.47 vs. $160.00. The patents are simply worrhless, you counter with insults and crapola, but what you can't counter with is evidence of any impact on stock price! One round knockout against the stupidest person on the face f the earth - that be you dummy!
Bud - tell me how much revenue has been generated from these patents over the last ten plus years. Don't stutter, produce a number. You can't and that makes your post worthless like over 300+ of the patents you mentioned. You and the moron that started this thread has done a #$%$ poor job of research. You are more than desperate. Jacksucjs, you suck and Eisai sucks. Do you know that Ralinepag wgisevPhase 2b study won't be completed until mid-2017. Do you know that? This thread is pitiful! Get a clue and get a life.
The patents have not generated one nickel value. We are taking good 10+ years of patents but no value at all.
You are the fool, so look in the mirror before making a post proving you and 17 others are total stupid #$%$ dummies. You want to debate it? Come on dumb butt, you show me the revenue generated by the hundreds of make work patents that Arena has in there patient portfolio. You made the statement, back it up and back it up now with facts or declare yourself the Moron that you are. A patent an $1.89 will get you a cup of coffee at Starbucks. You and the morons that recommended this totally stupid post are the fools that have no clue of what you are talking about.
They might have the time but they don't have the sufficient cash for that time. I do think it is significant that Contrave passed B because B had a 72+ week head start.
Well why did CA in an Conference presentation last year state that 65K-70K doctors had written prescriptions for Belviq. Now they say that there are 36K steady prescribers.
The numbers do not add up based on the weekly scripts which continue this trend ________.
This Doctor doesn't know how many doctors are prescribing, that is his opinion that is based on what? As stated above, neither can Arena/Eisai get it right either.
You hit the nail on the head with your comment about why he would mention so much detail. In addition, he is an ER Doctor and the last thing anyone wants when they go to the ER is a doctor pumping them about a WL drug. Most ER's are so busy these days, it begs the question of where does he find the time. Not questioning that he does write prescriptions, since DCB has always been a reasonable poster but shouldn't there be questions about a Doctor pumping a drug on a financial board that he prescribes to people. Is it ethical?
Dr. Vig still is prescribing belviq but I think he has decided that with Hipaa being more stringent with confidentiality of PHI, that he has opted not to post patient response data on any investment board.
S9 - Arena does need to start responding to someone. Jack is just a hot dog vendor who hired a VP of Alliance Management that does what? Why don't you spend your time on the real issues instead of always defending the worst CEO in the World? I know you do all of this because you are making money day-trading. It is why you continue to pump the oil well hoping to get the price up, then sell and buy low again and then pump again.. your game is known.
You are just not believable anymore.
Unlike you and other's here, he a ton more smarter and knows that with Jack at the helm, Arena ain't going anywhere. He will finally go to a company where the stock options mean something and the stock price will actually grow. Now please go away, you are stinking up the joint and that is hard to do when the joint already stinks.
That is total BS! Provide the proof! You can't because you got it from a BS artist as well.
He quit because he knows that moocho money is needed since Eisai can't sell dog bones to dogs.
He also knows that he can find an opportunity with a Biotech that will within less than a year will have a share price that Arena will never have! Get your facts straight and from the right source.
Your source is a dumb #$%$!
Somewhat dismayed, they are very dismayed the 5-6 members I have communicated with S9.
Christine is getting the axe sharpened for the hot dog vendor. Of course there is going to be a new COB since Jack stepped down in December, but Spector when asked about it, said it wasn't necessary to issue a press release.
What is this asinine comment supposed to mean. He left in Feb. 2011 and came back August 2011, let's see we are one month away from August 2015 which would mean he has been back for four years. You have always been a bit slippery with the facts.
Jack took him back because Hoffman knew the most about getting money that Arena needed. Your topic is stupid as all get out. Jack does not deserve one bit of loyalty, what a horse's wrong end you are for making up this BC! Most normal people don't stay in a job for 18 years in a company that has never made one nickel of profit for all the years in business. A few billion vs. minuscule revenue. Dano - with this post, take a walk off short pier with 100 pound barbells tied to your ankles and don't come back you freakin moron!
Craig is a good man but not CEO material. Of course the local dogcatcher can replace Jack….oh I forgot Jack was the local dogcatcher and I think he sold hot dogs at Petco park. I prefer that Jack gets tarred and feathered and hoisted on his #$%$ out of Arena, What does Jack do on a daily basis.
He is not a scientist as some continue to think, so he doesn't develop anything. He certainly has no sway over analysts covering Arena or is able to convince WS of Arena's pipeline value. So, exactly why should we keep him around. Spector negotiates the deals, so he can't do that. Craig Audet handles the regulatory and operational stuff, the VP of Alliance Management that no one including Jack know what she does, so Jack is not needed there. They have an excellent person that runs the NMR equipment, Jack can't do that. OH, I know, he does know how to load and unload ATM machines. He certainly does not know how to manage a partner to guide them to tremendous script growth.
Finally, no one is performing well at Arena from a shareholders perspective since the only thing that counts is a growing share price.
Here is a response from Craig Audet to my letter:
On Apr 23, 2015, at 6:48 PM, Craig Audet wrote:
I agree with Joseph...an excellent email. You make your points in a clear, cogent, concise, and (most importantly) respectful manner. While I don't necessarily agree with all your points, I understand your position and respect your opinions and will take them to heart.
Craig M. Audet, Ph.D.
Sr. Vice President, Operations & Head of Global Regulatory Affairs
Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
San Diego, CA 92121
The key Dano is delivering a letter that will hopefully get action, but the main issue is Eisai staying on as partner. If they stay on in the half-baked manner that they are currently doing, then it is time for a new partner. The word behind the scenes is that Eisai does want out of the partnership, but want to get paid back some of the money expended in their sales and marketing effort. They need the cash to continue forward with the Biogen partnership which is laid out as a major focus on their action plan discussed in my letter above.
I delivered another communication to them prior to the ASM that I could not attend this year.
That communication repeated some of the above but also pushed for them to put more teeth in their performance plan toward creating shareholder value.
Good luck and success with your letter.
2nd part of the letter:
The pipeline does appear to have good 'potential' drugs in it but still years away from approval and going to market.
Based on past pipeline performance, there are no guarantees of success or partnerships.
The key point that I want to address Jack, is what steps are you taking to address the actual commitment of Eisai to Belviq other than pretty words. In my opinion and the opinion of some other investors, Arena should look at removing itself from the partnership agreement and finding a much better partner candidate that does have the real marketing and sales expertise to make Belviq a blockbuster in weight management and smoking cessation. I realize this is not easy and also know that if ongoing discussions are taking place to make this happen, Arena (you) would be unable to talk about it.
On the other hand, if Arena/Eisai plans on continuing the partnership, we investors need to know that and not just with a few statements but a more detailed letter/conference call outlining the details of moving forward and what actions Eisai will be taking to get Belviq going forward at a faster clip, because despite the "boom and bust" statement made, we do need faster action from Eisai. The "slow crawl" is nonsense and is not a viable strategy. In addition, it appears Eisai's efforts in ROW is lackluster to say the least.
In addition Jack, you really need to look at restructuring Arena for true profitability. Yes, this means cutting back headcount and even making a decision to place focus on the one pipeline candidate that has the most market, partnership and approval opportunity. Pick one and keep the other two in "hold" status.
I personally do not need a direct response, what is needed is a proper response to Arena shareholders either in a letter or a special CC or both would be my recommendation. As shareholders, we really need to understand in greater detail so that we can make a more informed decision about our Arena investment. TBC.